Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials

被引：0
|
作者：
Sandborn, W. J. [1 ]
Panes, J. [2 ]
D'Haens, G. R. [3 ]
Sands, B. E. [4 ]
Su, C. [5 ]
Moscariello, M. [5 ]
Jones, T. V. [5 ]
Pedersen, R. D. [5 ]
Friedman, G. S. [5 ]
Lawendy, N. [5 ]
Chan, G. [5 ]
机构：
[1] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA
[2] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
[3] Acad Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands
[4] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA
[5] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP023
引用
收藏
页码：S45 / S46
页数：3
相关论文
共 50 条
  • [21] Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: An Update of Results From the OCTAVE Clinical Trials
    Panes, Julian
    Colombel, Jean-Frederic
    Vermeire, Severine
    Dubinsky, Marla C.
    Sharara, Ala
    Lawendy, Nervin
    Wang, Wenjin
    Salese, Leonardo
    Su, Chinyu
    Modesto, Irene
    Guo, Xiang
    Loftus, Edward V., Jr.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S332 - S333
  • [22] Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients
    Colombel, Jean-Frederic
    Ghosh, Subrata
    Sandborn, William
    Van Assche, Gert A.
    Reinisch, Walter
    Lazar, Andreas
    Eichner, Samantha
    Huang, Bidan
    Robinson, Anne
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S231 - S232
  • [23] Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program
    Winthrop, Kevin L.
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Salese, Leonardo
    Thorpe, Andrew J.
    Lawendy, Nervin
    Chan, Gary
    Pedersen, Ronald D.
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S427 - S429
  • [24] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
    Sands, Bruce E.
    Taub, Pam R.
    Feagan, Brian G.
    Armuzzi, Alessandro
    Friedman, Gary S.
    Moscariello, Michele
    Lawendy, Nervin
    Pedersen, Ronald D.
    Chan, Gary
    Nduaka, Chudy I.
    Quirk, Daniel
    Salese, Leonardo
    Su, Chinyu
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S380
  • [25] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Friedman, G. S.
    Moscariello, M.
    Lawendy, N.
    Pedersen, R. D.
    Chan, G.
    Nduaka, C. I.
    Quirk, D.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S23 - S23
  • [26] Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
    Winthrop, Kevin L.
    Loftus, Edward V. Jr Jr
    Baumgart, Daniel C.
    Reinisch, Walter
    Nduaka, Chudy, I
    Lawendy, Nervin
    Chan, Gary
    Mundayat, Rajiv
    Friedman, Gary S.
    Salese, Leonardo
    Thorpe, Andrew J.
    Su, Chinyu
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 914 - 929
  • [27] Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme
    Ungaro, R. C.
    Ciorba, M. A.
    Rogler, G.
    Sharara, A. I.
    Sunna, N.
    Connelly, S. B.
    Mundayat, R.
    Lawendy, N.
    Panes, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S357 - S359
  • [28] Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
    Rubin, D. T.
    Torres, J.
    Regueiro, M.
    Reinisch, W.
    Prideaux, L.
    Kotze, P. G.
    Tan, F. H.
    Gardiner, S.
    Mundayat, R.
    Cadatal, M. J.
    Ng, S. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I506 - I507
  • [29] Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
    Rubin, D. T.
    Torres, J.
    Regueiro, M.
    Reinisch, W.
    Prideaux, L.
    Kotze, P. G.
    Tan, F. H.
    Gardiner, S.
    Mundayat, R.
    Cadatal, M. J.
    Ng, S. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I506 - I507
  • [30] Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
    Mishra, Shubhra
    Jena, Anuraag
    Kakadiya, Rinkalben
    Sharma, Vishal
    Ahuja, Vineet
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (08) : 737 - 752
12345